Circulating Tumor DNA (ctDNA)-Guided Late-Line Treatment in Patients With Late-Stage Breast Cancer
This is a retrospective, observational, multi-center clinical study of circulating tumor DNA (ctDNA) to guide late-line therapy in late-stage metastatic breast cancer patients.
Full Title of Study: “Clinical Application of Circulating Tumor DNA (ctDNA) to Guided the Late-Line Treatment for Patients With Late-Stage Breast Cancer”
- Study Type: Observational
- Study Design
- Time Perspective: Retrospective
- Study Primary Completion Date: June 30, 2019
This study aims to evaluate the feasibility of plasma ctDNA mutation in guiding late-line treatment for late-stage metastatic breast cancer patients. Meanwhile, this study tries to evaluate the curative effect of ctDNA subtype-guided late-line therapy.
- Drug: Control group
- Physician chosen treatment
- Drug: Case group
- Druggable ctDNA alterations-guided therapy
Arms, Groups and Cohorts
- Control group
- Control group includes patients without ctDNA abnormality and patients without druggable ctDNA abnormality.
- Case group
- Case group includes patients with druggable ctDNA abnormality.
Clinical Trial Outcome Measures
- Disease Control Rate (DCR)
- Time Frame: From the beginning of the treatment to the end of Cycle 2 (each cycle is 28 days) of treatment.
- The total rate of CR+PR+SD after the completion of two cycles of late-line therapy.
- Progression-Free Survival
- Time Frame: From date of recruitment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months.
- The survival time between the beginning of treatment to death or the progression.
Participating in This Clinical Trial
- Recent progression of TNBC after multiple lines of chemotherapy or of HR+ or HER2+ MBC after multiple lines of endocrine or targeted therapy; – No available recommendation for the next treatment regimen; – An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2; – An updated, available pathological HR/HER2 status for metastasis; – According to RECIST 1.1 standard, there should be at least one measurable target lesion; – The expected survival time is > 3 months; – Those aged 18-70 years old; – Liver and kidney function and blood routine test meet the following conditions: Neutrophil > 2.0g/l, Hb > 9g / L, PLT > 100g / L; ALT and AST < 2.5ULN; TBIL < 1.5ULN; Cr < 1.0ULN – Signing informed consent; – Those willing to accept polygenic testing. Exclusion Criteria:
- Patients with multiple primary tumors; – Those who are unable to obtain blood samples; – Those with a history of immunodeficiency or organ transplantation; – Those with abnormal cardiac function or previous history of myocardial infarction or serious arrhythmia; – The researchers think it is not suitable to participate in this experiment.
Gender Eligibility: Female
Minimum Age: 18 Years
Maximum Age: 70 Years
Are Healthy Volunteers Accepted: No
- Lead Sponsor
- Hunan Cancer Hospital
- Provider of Information About this Clinical Study
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.